Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.
Three patients with diffuse large B-cell type of post-transplant lymphoproliferative disease after lung transplantation were treated with rituximab, an anti-CD20 monoclonal antibody. Treatment resulted in two complete remissions and one non-response.